



Tissue Regeneration Therapeutics Inc. receives notice of latest patent grant from the United States Patent Office

Toronto, Canada, March 30th 2015: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has received notice from the United States Patent and Trademark Office that its patent: GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL OR CHEMICAL AGENTS, will be granted on April 14th, 2015 as US patent 9,005,599.

This latest addition to the TRT patent portfolio further validates and strengthens the TRT technology platform. TRT is currently collaborating with the Defence Research and Development Canada (DRDC-s) of the Department of National Defence (DND) Canada. This patent has already been allowed in Australia and is pending in all other major territories worldwide.

TRT is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP family of cell therapy products. TRT has discovered the world's richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal cells within the harvested population, their increased biological potential compared to cells derived from adult tissues and their inexhaustible supply.

About TRT

TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP cell therapy products. TRT is the only company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the regenerative medicine, defense, and family banking sectors. Additional information is available at <http://www.verypowerfulbiology.com>